Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Obsidian Therapeutics, Inc.Startup |
Active Organization Obsidian Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endocrinology and Metabolic Disease | Discovery | - | Obsidian Therapeutics, Inc.Startup | 21 Sep 2023 |
Rare Diseases | Discovery | - | Obsidian Therapeutics, Inc.Startup | 21 Sep 2023 |
Urogenital Diseases | Discovery | - | Obsidian Therapeutics, Inc.Startup | 21 Sep 2023 |